Johnson & Johnson buy Guggenheim
Start price
23.09.25
/
50%
€148.72
Target price
23.09.26
€174.32
Performance (%)
4.17%
Price
29.09.25
€154.92
Summary
This prediction is currently active. With a performance of 4.17%, the BUY prediction by Guggenheim for Johnson & Johnson is trending in the right direction. This prediction currently runs until 23.09.26. The prediction end date can be changed by Guggenheim at any time. Guggenheim has 50% into this predictionJohnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Johnson & Johnson | 4.17% |
| iShares Core DAX® | 0.378% |
| iShares Nasdaq 100 | -0.117% |
| iShares Nikkei 225® | -0.806% |
| iShares S&P 500 | 0.059% |
Comments by Guggenheim for this prediction
In the thread Johnson & Johnson diskutieren
Johnson & Johnson (NYSE:JNJ) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $206.00 price target on the stock, up previously from $167.00.
Ratings data for JNJ provided by MarketBeat